Literature DB >> 29564173

Complete pathologic response is independent of the timing of esophagectomy following neoadjuvant chemoradiation for esophageal cancer.

Smit Singla1, Emmanuel Gabriel2, Raed Alnaji3, William Du3, Kristopher Attwood4, Hector Nava1, Steven N Hochwald1, Moshim Kukar1.   

Abstract

BACKGROUND: The relationship of complete pathologic response (cPR) with the timing of esophagectomy after neoadjuvant chemoradiation (nCRT) is not well defined. We sought to determine if a delay in esophagectomy after nCRT would result in increased likelihood of cPR and improved survival.
METHODS: This is a retrospective analysis of a prospectively maintained database of all patients treated with nCRT and esophagectomy between 2004 and 2014. Patients were divided into two groups based on timing of esophagectomy (≤50 vs. >50 days) after completion of nCRT. Survival outcomes were compared using standard Kaplan-Meier curves, and multivariable analyses were performed using Cox regression models.
RESULTS: This study included 226 patients (males, 211 and median age, 61 years) for analysis. Fifty-two patients (23%) in the early group (≤50 days) were compared to 174 patients (77%) in the delayed group (>50 days). The two groups were similar with respect to age, gender, comorbid conditions, ECOG status, location, grade, and tumor histology. There was no statistically significant difference in cPR rate between the early and late groups (26.9% vs. 19.0%, respectively, P=0.24). On multivariable analysis, lower age, absence of signet cell histology, better ECOG status, shorter length of stay and cPR were independent predictors of improved survival. The median follow-up was 52 months (range, 2-110 months), and there was no difference in the median overall survival (OS) between the early and late groups (48.9 vs. 42.6 months, respectively, P=0.73).
CONCLUSIONS: This analysis of a large cohort of patients with esophageal cancer undergoing multi-modality therapy shows that cPR is independent of the timing of esophagectomy. Other considerations for the timing of surgery, including recovery from nCRT and patient performance, may have more relevant roles than cPR when deciding when to perform esophagectomy.

Entities:  

Keywords:  Esophageal cancer surgery; esophageal adenocarcinoma; esophageal cancers

Year:  2018        PMID: 29564173      PMCID: PMC5848031          DOI: 10.21037/jgo.2017.09.11

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  24 in total

1.  Interval between neoadjuvant chemoradiotherapy and surgery for squamous cell carcinoma of the thoracic esophagus: does delayed surgery have an impact on outcome?

Authors:  Alberto Ruol; Christian Rizzetto; Carlo Castoro; Matteo Cagol; Rita Alfieri; Gianpietro Zanchettin; Francesco Cavallin; Silvia Michieletto; Gianfranco Da Dalt; Vanna Chiarion Sileni; Luigi Corti; Silvia Mantoan; Giovanni Zaninotto; Ermanno Ancona
Journal:  Ann Surg       Date:  2010-11       Impact factor: 12.969

2.  Novel Calculator to Estimate Overall Survival Benefit from Neoadjuvant Chemoradiation in Patients with Esophageal Adenocarcinoma.

Authors:  Emmanuel Gabriel; Kristopher Attwood; Rupen Shah; Steven Nurkin; Steven Hochwald; Moshim Kukar
Journal:  J Am Coll Surg       Date:  2017-01-29       Impact factor: 6.113

3.  Prolonged time to surgery after neoadjuvant chemoradiotherapy increases histopathological response without affecting survival in patients with esophageal or junctional cancer.

Authors:  Joel Shapiro; Pieter van Hagen; Hester F Lingsma; Bas P L Wijnhoven; Katharina Biermann; Fiebo J W ten Kate; Ewout W Steyerberg; Ate van der Gaast; J Jan B van Lanschot
Journal:  Ann Surg       Date:  2014-11       Impact factor: 12.969

4.  Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer.

Authors:  K Nygaard; S Hagen; H S Hansen; R Hatlevoll; R Hultborn; A Jakobsen; M Mäntyla; H Modig; E Munck-Wikland; B Rosengren
Journal:  World J Surg       Date:  1992 Nov-Dec       Impact factor: 3.352

5.  Comparative analysis of basaloid and conventional squamous cell carcinomas of the esophagus: prognostic relevance of clinicopathological features and protein expression.

Authors:  Yukie Sato-Kuwabara; José Humberto T G Fregnani; Juliano Jampietro; Katia Cândido Carvalho; Carolina Parucce Franco; Wilson Luís da Costa; Felipe J F Coimbra; Fernando Augusto Soares
Journal:  Tumour Biol       Date:  2015-12-09

6.  Increasing the Interval Between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer: A Meta-analysis of Published Studies.

Authors:  Fausto Petrelli; Giovanni Sgroi; Enrico Sarti; Sandro Barni
Journal:  Ann Surg       Date:  2016-03       Impact factor: 12.969

7.  A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus.

Authors:  E Le Prise; P L Etienne; B Meunier; G Maddern; M Ben Hassel; D Gedouin; D Boutin; J P Campion; B Launois
Journal:  Cancer       Date:  1994-04-01       Impact factor: 6.860

8.  Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report.

Authors:  A A Forastiere; M B Orringer; C Perez-Tamayo; S G Urba; M Zahurak
Journal:  J Clin Oncol       Date:  1993-06       Impact factor: 44.544

9.  Frequent amplification of ORAOV1 gene in esophageal squamous cell cancer promotes an aggressive phenotype via proline metabolism and ROS production.

Authors:  Yosuke Togashi; Tokuzo Arao; Hiroaki Kato; Kazuko Matsumoto; Masato Terashima; Hidetoshi Hayashi; Marco A de Velasco; Yoshihiko Fujita; Hideharu Kimura; Takushi Yasuda; Hitoshi Shiozaki; Kazuto Nishio
Journal:  Oncotarget       Date:  2014-05-30

10.  Prognostic relevance of autophagy markers LC3B and p62 in esophageal adenocarcinomas.

Authors:  Olivia Adams; Bastian Dislich; Sabina Berezowska; Anna M Schläfli; Christian A Seiler; Dino Kröll; Mario P Tschan; Rupert Langer
Journal:  Oncotarget       Date:  2016-06-28
View more
  4 in total

1.  Prognostic models for stage I-III esophageal cancer: a comparison between existing calculators.

Authors:  Riccardo Lemini; Tamara Díaz Vico; Denslow A Trumbull; Kristopher Attwood; Aaron C Spaulding; Enrique F Elli; Dorin T Colibaseanu; Moshim Kukar; Emmanuel Gabriel
Journal:  J Gastrointest Oncol       Date:  2021-10

2.  PATHOLOGIC COMPLETE RESPONSE (YPT0 YPN0) AFTER CHEMOTHERAPY AND RADIOTHERAPY NEOADJUVANT FOLLOWED BY ESOPHAGECTOMY IN THE SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS.

Authors:  Nelson Adami Andreollo; Giovanni de Carvalho Beraldo; Iuri Pedreira Filardi Alves; Valdir Tercioti-Junior; José Antonio Possato Ferrer; João de Souza Coelho-Neto; Luiz Roberto Lopes
Journal:  Arq Bras Cir Dig       Date:  2018-12-06

3.  Time to surgery in thoracic cancers and prioritization during COVID-19: a systematic review.

Authors:  Scott C Fligor; Savas T Tsikis; Sophie Wang; Ana Sofia Ore; Benjamin G Allar; Ashlyn E Whitlock; Rodrigo Calvillo-Ortiz; Kevin Arndt; Mark P Callery; Sidhu P Gangadharan
Journal:  J Thorac Dis       Date:  2020-11       Impact factor: 2.895

4.  Association between time interval from neoadjuvant chemoradiotherapy to surgery and complete histological tumor response in esophageal and gastroesophageal junction cancer: a national cohort study.

Authors:  F Klevebro; K Nilsson; M Lindblad; S Ekman; J Johansson; L Lundell; N Ndegwa; J Hedberg; M Nilsson
Journal:  Dis Esophagus       Date:  2020-05-15       Impact factor: 3.429

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.